The New York Times today published an op-ed by David Mitchell, cancer patient and founder of Patients For Affordable Drugs.

Instead of enjoying my retirement and focusing on my health, I carry around the overwhelming burden of Imbruvica’s price.

As The Fight To Lower Drug Prices Ramps Up, Audrey Baker Will Lead P4AD’s Communications Efforts

A system that allows runaway drug prices like these places a burden not only on patients themselves, but on everyone in this country by way of the outsized financial responsibility paid by taxpayers.

My symptoms shouldn’t worsen just because a drug company wants to make a few extra dollars of profit off of my diagnosis.

By the time I was about to turn 19, I was almost out of insulin and I ended up in diabetic ketoacidosis –– a serious condition that can lead to death.

Between the high cost of insulin and other supplies, affording the necessary treatments to survive as a diabetic can be incredibly costly.

New Report Debunks Pharma's Claim That Any Restraint On Its Unilateral Pricing Power Will Destroy Innovation And Access To New Medicines.